Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas

On Friday, Johnson & Johnson (NYSE:JNJ) announced that treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment.  

Data from the Phase 3b SPECTREM study to measure skin clearance and other treatment outcomes in low BSA moderate PsO with involvement across four special sites (scalp, face, skin folds, and genitals) and previous topical treatment failure were presented at the 2024 Fall Clinical Dermatology Conference.

Also Read: Justice Department’s Trustee Program Alleges Johnson & Johnson’s Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid ...